Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 118.76K | Year: 2002
NanoBioMagnetics? objective is to develop and commercialize magnetic nanoparticles as middle ear implants for hearing restoration. Hearing loss currently impairs over 24 million Americans. Emerging implantable electromagnetic hearing device (IHD) technology is proving to be safe and effective. Clinical advancement of IHD technology could be achieved through miniaturization of the magnetic implants. Phase 1 will demonstrate feasibility of preparing hermetic ferromagnetic nanoparticles and attaching them to middle ear ossicles. Two different encapsulation technologies will be evaluated: 1) Thermal Plasma Deposition (TPD): rf-Inductive Plasma will be used to create layered films in which nanoparticles are sandwiched within layers of titanium. 2) Nano-Layer Deposition (LBL): Polyelectrolytes in appropriate media will be used as effective templates for nano-layered films comprised of titanium encapsulated ferrite materials. Overcoating of nanoparticles with collagen Type 1 will be evaluated by implantation onto the middle ear ossicles of guinea pigs. Timed harvesting of tissues, histological staining for iron, and photomicroscopy will document cellular attachment and hermeticity. Phase 2 will scale device production methods, predict human performance using temporal bones and laser interferometry and define clinical applications. Commercialization is available through an Oklahoma IHD company, anticipating FDA approval of their device in August.
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 99.97K | Year: 2010
This Small Business Innovation Research (SBIR) Phase I project aims to develop a tumor-specific delivery technology based on the use of superparamagnetic nanoparticles as vehicles for the delivery of paclitaxel. The magnetic vectoring drug delivery platform uses external shaped magnetic field gradients to concentrate nanoparticle-drug constructs at a target site, followed by tumor extravasation. This project will focus on the treatment of superficial tumors, such as locally advanced breast cancers (LABC). These tumors pose a difficult and, as yet, unresolved clinical problem as most patients presenting with this disease will experience resistance and pronounced toxicity for current therapeutics. Therefore, a significant need exists for advanced therapies that can improve patient outcomes. A key distinguishing feature of this technology is the potential to overcome tumor interstitial pressure that normally tends to thwart free drug penetration.
The broader/commercial impact of this project will be the potential to provide localized delivery of therapeutics in a manner that improves both therapeutic and economic benefits to patients. The urgency for such advanced delivery methods is increasing as new classes of pharmaceuticals, such as siRNAs and stem cells, are being developed and brought to market. Because these new therapeutics are more effective through localized therapy, advanced delivery systems that support their full therapeutic potential must be developed. The capacity to magnetically vector therapeutics, tumor-specifically, will have a significant impact on both patient treatment strategies and outcomes.